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Abstract
Background: Surprisingly little is known about asthma control among asthmatics who smoke. The aim of this
cross-sectional study was to investigate asthma symptom control according to the GINA guidelines among
asthmatics with a clinically significant smoking history.
Methods: One hundred ninety asthmatics from primary care in Finland were investigated. The patients were
current or previous cigarette smokers with a history of 10 or more pack-years. They completed a questionnaire
including questions on asthma symptoms and reliever use so that their level of asthma symptom control (well
controlled, partly controlled, or uncontrolled) according to GINA could be determined.
Results: Sixty-six (34.7%) patients had their asthma well controlled, 81 (42.6%) had their asthma partly controlled,
and 43 (22.6%) had uncontrolled asthma. Current smokers had uncontrolled asthma more often than ex-smokers,
OR 2.54 (95% CI 1.25–5.14, p = 0.01). Patients with moderate to severe asthma exacerbation during the previous
year had uncontrolled asthma more often than patients without an exacerbation, OR 2.17 (95% CI 1.06–4.47, p = 0.04),
and patients with FEV1 < 80% of predicted had uncontrolled asthma more often than patients with FEV1 > 80% of
predicted, OR 2.04 (95% CI 1.02–4.08, p = 0.04).
Conclusions: Asthmatic patients with a clinically significant smoking history often do not have well controlled asthma.
Poor asthma symptom control was associated with current smoking status, history of exacerbations and impaired lung
function. Therefore, every attempt should be made to help asthmatics who smoke to quit smoking.
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Background
Asthmatic patients smoke roughly as often as the gen-
eral population. Approximately 20% of asthmatics are
smokers [1–3]. Among asthmatic patients, smoking is
associated with increased morbidity and mortality, a
higher frequency of asthma exacerbations, accelerated
decline of lung function, reduced response to inhaled
corticosteroids, and increased asthma severity, when
compared to non-smoking asthmatics [4, 5].
It has been shown that, smoking, especially currently
but also previously, is associated with poorer asthma
control levels [6–9]. However, surprisingly little is
known about asthma symptom control among asth-
matics who smoke.
The aim of this study was to investigate asthma symp-
tom control according to GINA guidelines [10] among
primary care asthmatic patients who are either current
or ex-smokers and to determine the patient characteris-
tics that may be associated with asthma control level.
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Methods
As part of our previous study assessing the prevalence of
undiagnosed asthma-COPD overlap among subjects with
asthma and a smoking history, asthmatic subjects with a
smoking history of at least 10 pack-years were recruited
during their primary health care visits in Finland [11].
The inclusion criteria were age 18–70 years, current or
ex-smoker with 10 or more pack-years and doctor-
diagnosed asthma. The exclusion criteria were any se-
vere illness, any known pulmonary disease other than
asthma, and the use of an inhaled anticholinergic or
indacaterol or oral roflumilast (to exclude subjects with
COPD).
In addition to measuring spirometry (Medikro, Kuo-
pio, Finland) and collecting information on demograph-
ics, smoking history, medical history and medication, a
questionnaire (Additional file 1) including questions set
according to the GINA guidelines [10] was filled so that
the asthma control level (well controlled, partly con-
trolled, or uncontrolled) could be determined.
Patients were considered to have had a moderate to
severe asthma exacerbation during the previous year if
they had been hospitalized or had used a course of oral
corticosteroids for their asthma during the previous
year.
The primary outcome variable was asthma symptom
control according to the GINA guidelines (well con-
trolled, partly controlled or uncontrolled). Baseline char-
acteristics of patients with well-controlled, partly
controlled and uncontrolled asthma were compared
using the Kruskal-Wallis test for continuous variables
and the chi-squared test for categorical variables. The
Jonckheere-Terpstra test for trends was applied if the
Kruskal-Wallis test yielded a significant association, and
the Mantel-Haenzel test for trends was applied if the
chi-squared test yielded a significant association. Univar-
iate logistic regression analyses were performed to assess
the association of asthma control with patient character-
istics. Before analysis, the 3 asthma control categories
were dichotomized in separate analyses as follows: well
controlled versus partly controlled and uncontrolled; un-
controlled versus well and partly controlled. In other
words, the opposite categories, well-controlled asthma
and uncontrolled asthma, were set as separate dependent
variables. Independent variables that were significant or
almost significant (p < 0.10) factors in the univariate
models were introduced into the multivariate models.
Multivariate logistic regression analyses were then per-
formed using the forward and backward stepping covari-
ate selection procedures. At each step, the criterion for
entry was p < 0.05 and that for removal was p > 0.05.
First-order interactions between the covariates were
tested. The results are given as odds ratios (ORs) with
95% confidence intervals (95% CIs).
P-values less than 0.05 were considered statistically
significant. The analyses were performed using IBM
SPSS Statistics for Windows (version 25.0, Armonk, NY,
USA, IBM Corp.).
Results
One hundred ninety patients were investigated (Table 1).
Their median age (range) was 58 (23–70) years, they had
smoked for 20 (10–60) pack-years, and their BMI was
27.5 (16.1–50.3) kg/m2. Inhaled corticosteroids (ICS)
were used by 179 (94.2%) patients, and leukotriene an-
tagonists were used by 34 (17.9%) patients. One hundred
twenty-two (64.2%) of the patients were using both ICS
and inhaled long-acting B2-adrenergic (LABA). Eighty-
three (44.1%) of the patients were current smokers, and
78 (41.1%) were male.
Sixty-six (34.7%) patients had their asthma well con-
trolled, 81 (42.6%) had their asthma partly controlled,
and 43 (22.6%) were uncontrolled.
The proportions of current smokers (p = 0.02) and pa-
tients with exacerbations during the previous year (p =
0.001) were different among asthma control categories.
There was also a difference between the groups in FEV1
(% predicted) (Table 1). The proportion of current
smokers and patients who had an asthma exacerbation
during the previous year decreased when the level of
asthma control improved (trend test p = 0.01 and p <
0.001, respectively). Similarly, FEV1 (% predicted) im-
proved as asthma control improved (trend test p = 0.03).
The unadjusted analysis of asthma symptom control
according to the patient characteristics is shown in
Table 2. Current smokers had uncontrolled asthma
more often than ex-smokers (31% vs. 15%), OR 2.54
(95% CI 1.25–5.14, p = 0.01). Patients who had asthma
exacerbations during the previous year had uncontrolled
asthma more often than patients without exacerbations
(33% vs. 19%), OR 2.17 (95% CI 1.06–4.47, p = 0.04). Pa-
tients with significant reversibility in spirometry tended
to have uncontrolled asthma more often than patients
without significant reversibility (41% vs. 21%), OR 2.66
(95% CI 0.95–7.49, p = 0.06), and patients with FEV1 less
than 80% of predicted had uncontrolled asthma more
often than patients with FEV1 more than 80% of pre-
dicted (29% vs. 17%), OR 2.04 (95% CI 1.02–4.08, p =
0.04). A smoking history of at least 30 pack-years was re-
lated to uncontrolled asthma, OR 1.99 (95% CI 0.98–
4.05, p = 0.06). The final multivariate logistic regression
model showed that patients with current smoking (OR
2.38, 95% CI 1.14–4.99, p = 0.02), smoking history of at
least 30 pack-years (OR 2.62, 95% CI 1.21–5.64, p =
0.01), exacerbation during the previous year (2.73, 95%
CI 1.24–6.04, p = 0.01) or significant reversibility (OR
3.91, 95% CI 1.27–12.09, p = 0.02) had significantly more
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Table 1 Patient characteristics for the whole group of asthmatics who had a smoking history of at least 10 pack-years, and










Age (years) 58.0 (50.0–65.0) 59.5 (52.0–65.0) 57.0 (49.0–65.0) 58.0 (49.0–64.0) 0.79
Females 112 (58.9) 36 (54.5) 46 (56.8) 30 (69.8) 0.25
BMI (kg/m2) 27.5 (24.2–31.1) 26.3 (24.2–30.1) 27.5 (24.3–31.2) 27.9 (23.9–33.3) 0.47
Current smokers 83 (44.1) 23 (35.4) 34 (42.0) 26 (61.9) 0.02 (0.01)***
Pack-years 20.0 (15.0–30.0) 20.0 (15.0–30.0) 20.0 (15.0–27.0) 26.0 (15.0–35.0) 0.25
FEV1 (% of predicted) 80.5 (71.0–93.0) 84.0 (71.0–94.0) 83.0 (72.0–95.0) 78.0 (67.0–83.0) 0.03 (0.03)
**
Significant reversibility in FEV1 17 (8.9) 5 (7.6) 5 (6.2) 7 (16.3) 0.15
Post-bronchodilator FEV1/FVC 0.74 (0.68–0.79) 0.73 (0.68–0.77) 0.75 (0.70–0.81) 0.72 (0.68–0.80) 0.24
Post bronchodilator FEV1/FVC < 0.70 52 (27.4) 17 (25.8) 22 (27.2) 13 (30.2) 0.88
Exacerbation during previous year 51 (26.8) 7 (10.6) 27 (33.3) 17 (39.5) 0.001 (< 0.001)***
Regular use of inhaled corticosteroid 179 (94.2) 63 (95.5) 77 (95.1) 39 (90.7) 0.53
Regular use of inhaled corticosteroid +
long-acting b2-agonist (ICS + LABA)
122 (64.2) 42 (63.6) 56 (69.1) 24 (55.8) 0.34
The results are given as the median (interquartile range) or number of patients (percentage)
*Kruskal-Wallis test was used for continuous variables, and the chi-squared test was used for comparisons of categorical variables among groups according to
asthma control
**Jonckheere-Terpstra trend test in parentheses
***Mantel-Haenzel trend test in parentheses
Table 2 Asthma symptom control according to patient characteristics. Univariate logistic regression analysis was used to analyse the
associations with the asthma control levels ‘Well controlled’ and ‘Uncontrolled’













OR 95% CI P OR 95% CI P
Smoking Ex-smoker (N = 105) 42 (40.0) 47 (44.8) 16 (15.2)
Current smoker
(N = 83)
23 (27.7) 34 (41.0) 26 (31.3) 0.58 0.31–1.07 0.08 2.54 1.25–5.14 0.01
Pack-years < 30 (N = 133) 47 (35.3) 61 (45.9) 25 (18.8)
≥30 (N = 57) 19 (33.3) 20 (35.1) 18 (31.6) 0.91 0.47–1.76 0.79 1.99 0.98–4.05 0.06
Sex Female (N = 112) 36 (32.1) 46 (41.1) 30 (26.8)
Male (N = 78) 30 (38.5) 35 (44.9) 13 (16.7) 1.32 0.72–2.41 0.37 0.55 0.26–1.13 0.10
Exacerbationa No (N = 139) 59 (42.4) 54 (38.8) 26 (18.7)
Yes (N = 51) 7 (13.7) 27 (52.9) 17 (33.3) 0.22 0.09–0.51 0.001 2.17 1.06–4.47 0.04
ICS No (N = 11) 3 (27.3) 4 (36.4) 4 (36.4)
Yes (N = 179) 63 (35.2) 77 (43.0) 39 (21.8) 1.45 0.37–5.65 0.59 0.49 0.14–1.75 0.49
ICS + LABA No (N = 68) 24 (35.3) 25 (36.8) 19 (27.9)
Yes (N = 122) 42 (34.4) 56 (45.9) 24 (19.7) 0.96 0.52–1.79 0.90 0.63 0.32–1.26 0.19
FEV1/FVC < 0.70
b No(N = 138) 49 (35.5) 59 (42.8) 30 (21.7)
Yes (N = 52) 17 (32.7) 22 (42.3) 13 (25.0) 0.88 0.45–1.73 0.72 1.20 0.57–2.53 0.63
FEV1, % of predicted ≥ 80% 40 (39.6) 44 (43.6) 17 (16.8)
< 80% 26 (29.2) 37 (41.6) 26 (29.2) 0.63 0.34–1.15 0.13 2.04 1.02–4.08 0.04
Significant reversibilityc No (N = 173) 61 (35.3) 76 (43.9) 36 (20.8)
Yes (N = 17) 5 (29.4) 5 (29.4) 7 (41.2) 0.77 0.26–2.27 0.63 2.66 0.95–7.49 0.06
ahospitalization and/or oral corticosteroids for asthma during the previous year, bpost-bronchodilator, cchange in FEV1 at least 12% and 200 ml
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often uncontrolled asthma. None of the tested inter-
action terms were significant.
Having well controlled asthma was not explained by
the same patient characteristics as having uncontrolled
asthma. Only two significant or almost significant associ-
ations were observed in the multivariate logistic regres-
sion. Patients with an exacerbation during the previous
year had less often well controlled asthma compared to
patients without an exacerbation (0.22, 95% CI 0.09–
0.51, p = 0.001), and currents smokers had less often
well controlled asthma compared to ex-smokers (0.58,
95% CI 0.31–1.07, p = 0.08) (Table 2).
Discussion
One third of asthmatics with a smoking history had their
asthma well controlled. The proportion is relatively low
and suggests that good asthma control among current or
ex-smokers is not often achieved in primary care, even in a
country like Finland where asthmatics in general do quite
well [1].
In a recent survey of 8000 European asthmatics, with
only 22.8% of the patients being current smokers, Price
et al. [2] found that only 20.1% of asthmatics had their
asthma well controlled according to the GINA guide-
lines. Compared to that, our finding that 34.7% of
current or ex-smoking asthmatics had their asthma well
controlled was surprisingly high. Most probably this is
due to fact that in our study practically all patients were
using inhaled corticosteroids regularly, which was not
the case in the study by Price et al. In the study by
Braido et al. [9], 43.5% of the patients had controlled
asthma. In that study 35% of patients were either current
or ex-smokers. However, they did not use GINA criteria
to define the asthma control level, and therefore their re-
sult cannot be directly compared with our result.
Our study included only subjects with a smoking his-
tory of at least 10 pack-years, and we cannot therefore
make any conclusions regarding comparisons with non-
smokers with asthma in Finland. Based on a recent re-
port on a cohort of adult asthmatics in Finland including
both smokers and non-smokers, 72% of the subjects had
well-controlled asthma defined as an Asthma Control
Test (ACT) score of at least 20 points [12]. This is a sig-
nificantly higher proportion than in our study. Although
GINA symptom control and the ACT are not identical,
they are quite similar, and this comparison supports pre-
vious findings suggesting that asthma symptom control
is on average poorer among subjects with a clinically sig-
nificant smoking history than among others. This is fur-
ther supported by the same group reporting that in their
cohort, asthma symptom control seemed to be worst in
those with the heaviest smoking history [13].
From the GOAL study, we learned that it is possible
to achieve good asthma control in at least 70% of cases
by stepping up asthma medication [14]. More than 94% of
our patients were using inhaled corticosteroids (ICS) regu-
larly, and 64.2% of the patients used ICS in combination
with long-acting β2-agonist (LABA). Nevertheless, only
one-third of our patients had their asthma well controlled.
This is most likely because our patients had smoked more
than 10 pack-years, and 44.1% of our patients were
current smokers, and smoking is known to reduce the re-
sponse to ICS [15, 16]. However, in the current study,
using both ICS and LABA increased the likelihood of
asthma being well controlled among the subgroup of
current smokers with an OR 3.39 (95% CI 1.03–11.20,
p = 0.04) compared with not using ICS and LABA.
Although 94.2% of our patients used inhaled corticoste-
roids, 64.2% in combination with LABA, and 17.9% of the
patients used leukotriene antagonists, we cannot state that
our patients were optimally treated. Namely, as we investi-
gated asthmatics who had smoked at least 10 pack-years,
with 27.4% of patients having a post-bronchodilator FEV1/
FVC < 0.70, suggesting the possibility of asthma-COPD
overlap syndrome [11], it is probable that more patients
would have had their asthma better controlled if they had
also used LAMA. This study is part of a project where we
assessed the prevalence of previously undiagnosed
asthma-COPD overlap among asthmatic subjects with a
smoking history. Therefore, subjects using drugs mostly
used to treat COPD at the time of recruitment (LAMA,
indacaterol, and roflumilast) were excluded. This was to
avoid recruiting subjects with a previous diagnosis of
COPD, but since some of the subjects with more severe
asthma are treated with LAMA, this criterion may have
excluded some subjects with more severe asthma.
We found that uncontrolled patients were current
smokers more often than well/partly controlled patients
(61.9% vs 39.0%; p = 0.009). The finding that current
smoking is associated with worse asthma control has
also been found by others [6, 8] and may reflect the fact
that cigarette smoke is known to reduce the response to
ICS in asthmatic patients [15, 16]. Furthermore, there is
good evidence that asthma outcome improves in several
ways after smoking cessation [3, 5], which is also in line
with our observation that ex-smokers had their asthma
better controlled than current smokers.
Conclusions
Asthmatic patients with a smoking history of at least 10
pack-years who are treated in primary health care are
often not well controlled. Poorer asthma symptom con-
trol was associated with current smoking, history of ex-
acerbations and impaired lung function. Therefore, every
attempt should be made to help asthmatics who smoke
to quit smoking and to prevent young asthmatics from
starting to smoke.
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Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12890-020-1127-9.
Additional file 1. Symptom questionnaire, presents an English
translation of the symptom questionnaire with criteria used for grading
asthma symptom control.
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